Universiteto vaistinė
At the beginning of 2010, the company was reorganized by connecting three companies: VĮ „Lazdynų vaistinė“, VĮ „Šaltinio vaistinė“ and VĮ „Vilniaus Gedimino vaistinė“. On 30 December 2011, the company was transformed into a private limited liability company. The main activities of „Universiteto vaistinė“ include trade in medicinal products, food supplements, hygiene products, and the manufacture and consultation of medicines in a pharmacy.
Financial results
P/L Statment
| 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|
| Revenue | 2,426 | 2,171 | 2,404 | 2,590 |
| Cost of goods sold | 1,716 | 1,521 | 1,709 | 1,844 |
| Gross profit (loss) | 710 | 651 | 695 | 746 |
| Gross profit margin | 29% | 30% | 29% | 29% |
| Operating expenses | 686 | 618 | 605 | 648 |
| Operating profit (loss) | 24 | 33 | 90 | 99 |
| Operating profit margin | 1% | 2% | 4% | 4% |
| EBITDA | 32 | 37 | 96 | 105 |
| EBITDA margin | 1% | 2% | 4% | 4% |
| Net profit (loss) | 24 | 29 | 76 | 82 |
| Net profit margin | 1% | 1% | 3% | 3% |
| 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | |
|---|---|---|---|---|
| Revenue | 1,143 | 1,165 | 1,308 | 1,072 |
| Cost of goods sold | 819 | 825 | 919 | 771 |
| Gross profit (loss) | 324 | 340 | 388 | 300 |
| Gross profit margin | 28% | 29% | 30% | 28% |
| Operating expenses | 315 | 321 | 317 | 280 |
| Operating profit (loss) | 9 | 19 | 72 | 21 |
| Operating profit margin | 1% | 2% | 5% | 2% |
| EBITDA | 11 | 22 | 75 | 24 |
| EBITDA margin | 1% | 2% | 6% | 2% |
| Net profit (loss) | 1 | 3 | 59 | 17 |
| Net profit margin | 1% | 1% | 4% | 2% |
Balance sheet
| 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|
| Non-current assets | 707 | 718 | 716 | 718 |
| Intangible assets | 0 | 4 | 3 | 2 |
| Tangible assets | 707 | 714 | 713 | 716 |
| Financial assets | ||||
| Other non-current assets | ||||
| Biological assets | ||||
| Current assets | 584 | 539 | 628 | 773 |
| Inventories and prepaid expenses | 322 | 294 | 304 | 354 |
| Accounts receivable in one year | 53 | 39 | 62 | 57 |
| Other current assets | ||||
| Cash and cash equivalents | 208 | 207 | 262 | 362 |
| Total assets | 1,297 | 1,263 | 1,349 | 1,491 |
| Equity | 1,104 | 1,106 | 1,154 | 1,178 |
| Minority share of capital | ||||
| Grants and subsidies | ||||
| Liabilities | 193 | 157 | 195 | 313 |
| Financial liabilities | ||||
| Long-term liabilities | ||||
| Short-term liabilities | 193 | 157 | 195 | 313 |
| Equity and liabilities | 1,297 | 1,263 | 1,349 | 1,491 |
| 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | |
|---|---|---|---|---|
| Non-current assets | 706 | 718 | 716 | 716 |
| Intangible assets | 0 | 3 | 2 | 1 |
| Tangible assets | 706 | 714 | 714 | 715 |
| Financial assets | ||||
| Other non-current assets | ||||
| Biological assets | ||||
| Current assets | 573 | 624 | 657 | 636 |
| Inventories and prepaid expenses | 304 | 339 | 345 | 319 |
| Accounts receivable in one year | 39 | 51 | 72 | 88 |
| Other current assets | ||||
| Cash and cash equivalents | 230 | 234 | 241 | 230 |
| Total assets | 1,280 | 1,342 | 1,379 | 1,353 |
| Equity | 1,085 | 1,094 | 1,155 | 1,124 |
| Minority share of capital | ||||
| Grants and subsidies | ||||
| Liabilities | 195 | 248 | 224 | 229 |
| Financial liabilities | ||||
| Long-term liabilities | ||||
| Short-term liabilities | 195 | 248 | 224 | 229 |
| Equity and liabilities | 1,280 | 1,342 | 1,379 | 1,353 |
Financial ratios
| 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|
| Capital return ratios | ||||
| Return on assets (ROA) | 2% | 2% | 6% | 6% |
| Return on equity (ROE) | 2% | 3% | 7% | 7% |
| Return on capital employed (ROCE) | 5% | 6% | 16% | 17% |
| Capital structure and liquidity ratios | ||||
| Debt / asset ratio (D/A) | ||||
| Current Ratio | 3.03 | 3.44 | 3.21 | 2.47 |
| Quick ratio | 1.36 | 1.57 | 1.66 | 1.34 |
| Turnover ratios | ||||
| Asset turnover | 1.82 | 1.70 | 1.84 | 1.82 |
| Fixed asset turnover | 3.43 | 3.05 | 3.35 | 3.61 |
| Equity turnover | 2.16 | 1.96 | 2.13 | 2.22 |
| Profitability ratios | ||||
| EBITDA margin | 1% | 2% | 4% | 4% |
| Operating profit margin | 1% | 2% | 4% | 4% |
| Net profit margin | 1% | 1% | 3% | 3% |
| Other ratios | ||||
| Dividends to the State | 27.80 | 27.93 | 56.99 | 71.60 |
| Dividends paid / net profit | 1.18 | 0.96 | 0.75 | 0.88 |
| 2017-06-30 | 2018-06-30 | 2019-06-30 | 2020-06-30 | |
|---|---|---|---|---|
| Capital return ratios | ||||
| Return on assets (ROA) | 2% | 3% | 9% | 3% |
| Return on equity (ROE) | 3% | 3% | 10% | 4% |
| Return on capital employed (ROCE) | 6% | 4% | 12% | 4% |
| Capital structure and liquidity ratios | ||||
| Debt / asset ratio (D/A) | ||||
| Current Ratio | 3.44 | 2.52 | 2.94 | 2.78 |
| Quick ratio | 1.57 | 1.15 | 1.40 | 1.39 |
| Turnover ratios | ||||
| Asset turnover | 1.70 | 0.89 | 0.96 | 0.78 |
| Fixed asset turnover | 3.05 | 1.64 | 1.82 | 1.50 |
| Equity turnover | 1.96 | 1.07 | 1.16 | 0.94 |
| Profitability ratios | ||||
| EBITDA margin | 2% | 2% | 6% | 2% |
| Operating profit margin | 2% | 2% | 5% | 2% |
| Net profit margin | 1% | 1% | 4% | 2% |
| Other ratios | ||||
| Dividends to the State | 27.93 | |||
| Dividends paid / net profit | 0.96 |
Financial statments
2015 m. 12 mėn. tarpinės ataskaitos
2015 m. 9 mėn. tarpinės ataskaitos
2015 m. 6 mėn. tarpinės ataskaitos
2015 m. 3 mėn. tarpinės ataskaitos
2014 m. metinės ataskaitos
2014 m. 12 mėn. tarpinės ataskaitos
2014 m. 3 mėn. tarpinės ataskaitos
2014 m. 6 mėn. tarpinės ataskaitos
2014 m. 9 mėn. tarpinės ataskaitos
Expectations of the state
Target return on equity
6.7%
About the company
- Official nameUAB Universiteto vaistinė
- Legal formPrivate limited liability company (UAB)
- Company code121466988
- SectorOther
- Line of businessPharmacies
- Institution representing the StateMinistry of Health
- Share belonging to the State100%
Return to the State
72 EUR thousand
ROE
7.0%
Number of employees
29
Financial data provided as at end-December 2019
Management
- Rima LosinskajaDirector General
Information as of: 2020/10/01
